Opinion on Pharmaceutical Manufacturers in Europe

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Governmental cost-cutting helps generate generics growth

The generic cancer market was worth $1.3 billion in 2004 and is expected to reach $10.9 billion by 2014. This staggering level of growth is attributable to upcoming patent expiries on key products, as well as the imminent introduction of a biogenerics regulatory pathway. However, increasingly cost-conscious governments working to cut healthcare spending will remain generics firms' greatest ally.

Published By Datamonitor
06 Mar 2006
Expert View
Expert View

New advertising code of conduct established in Vioxx withdrawal fallout

Recent high-profile drug withdrawals have resulted in a new code of conduct to govern direct-to-consumer advertising. As more and more drugs are likely to come under regulatory and public scrutiny, the pharmaceutical industry will need to employ effective marketing and education strategies to ensure patient and physician confidence is retained and the impact of drug safety scares is minimized.

Published By Datamonitor
09 Mar 2006
CommentWire
CommentWire

Speedel/Novartis: Rasilez and the renin revolution

Novartis stands on the brink of launching the first innovative treatment for hypertension in over a decade, in the form of Rasilez (aliskiren), thanks to the efforts of the drug's development partner, Speedel. This vindicates the risk Speedel took back in 1998 when it set out to build a business based on big pharma cast-offs, something many believed was doomed to fail.

Published By Datamonitor
10 Mar 2006
Expert View
Expert View

Drug reps must embrace technology to avoid missing sales opportunities

In a pharmaceutical market where the days of the primary care blockbuster-selling drug appear numbered, the days of pharma sales representatives having time to visit physicians with drug samples are also waning. Reps must now embrace internet technology to ensure samples are efficiently distributed to physicians and also take on the role of educators in their dynamic relationships with physicians.

Published By Datamonitor
15 Mar 2006
CommentWire
CommentWire

Schering AG/Merck KGaA: takeover tussles begin

The board of Schering AG has rejected Merck KGaA's $17.5 billion hostile takeover offer. Merck is unlikely to be deterred given that the buy would create Germany's second-largest pharma firm and enable Merck to significantly expand its portfolio. However, speculation suggests that Schering may now initiate a series of takeovers of its own to fend off Merck's advances.

Published By Datamonitor
16 Mar 2006
ResearchWire
ResearchWire

Pulmonary arterial hypertension: market on the pulse of global growth

Published By Datamonitor
17 Mar 2006
ResearchWire
ResearchWire

Vaccines: sales show global growth

Published By Datamonitor
17 Mar 2006
Expert View
Expert View

TeGenero Mab causes shock side-effects in UK trial

A phase I UK clinical trial of TeGenero's TGN1412 has stirred up a storm of controversy after trial participants suffered serious adverse events soon after taking the drug. While this event could have a number of implications for drug developers, it needs to be weighed against the need for new medicines, especially in chronic disorders.

Published By Datamonitor
17 Mar 2006
CommentWire
CommentWire

Merck/NicOx: more reinvention rather than innovation

Big pharma, in the shape of Merck & Co, has once again dipped its hand into the biopharma goody bag to bolster R&D pipelines. The deal, potentially worth around $350 million to NicOx, comes only days after NicOx inked a similar sized deal with Pfizer in ophthalmology, and should help boost Merck's lifecycle management efforts.

Published By Datamonitor
22 Mar 2006
CommentWire
CommentWire

Asthma and eczema: gene discovery could be the missing link

University of Dundee researchers have discovered a new gene that, when mutated, causes eczema and may be associated with asthma. An estimated 10% of the European population carries this mutation, sometimes leading to severe, uncontrolled disease requiring specialist treatment. However, while the discovery holds promise for new treatments for these patients, these drugs are still a long way off.

Published By Datamonitor
23 Mar 2006

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.